Biorestorative Therapies (BRTX)
(Delayed Data from NSDQ)
$1.22 USD
-0.07 (-5.43%)
Updated Jun 4, 2024 03:59 PM ET
After-Market: $1.22 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum D VGM
Brokerage Reports
Biorestorative Therapies, Inc. [BRTX]
Reports for Purchase
Showing records 1 - 20 ( 42 total )
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Developing Novel Exosome-Based Weight Loss Therapeutic
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Signs Commercial Deal with Medical Aesthetics Technology Company Cartessa
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Ongoing BRTX-100 Trial Can Use Sham Injection Control Rather Than Saline
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Galen To Help Speed Phase 2 Enrollment, Which Should Finish By YE24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
4Q23: Recent Encouraging Blinded Preliminary Phase 2 BRTX-100 Data in cLDD
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging, Albeit Blinded, Preliminary Phase 2 BRTX-100 Data in cLDD
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare: HC Opportunities Conference in NYC on October 12th
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Signs Potentially Lucrative Supply Agreement With Evolutionary Biologics
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Northwell Health Activated As a Phase 2 Trial Site for BRTX-100 in cLDD
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
2Q23: Low Valuation Undeserved, BRTX-100 Safe, 10-Q Filed, Cash Into 3Q24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Stock Weakness On Highly Misleading Chatroom Information, CEO Buys Shares
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
DSMB Unanimously Recommends Continuing Phase 2 cLDD Trial Without Changes
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Doses Final Safety Run-In Patient In Phase 2 cLDD Trial
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Licensed by NYS DoH as a Tissue Bank for Mesenchymal Stem Cell Processing
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J